EUVIMEDEUVIMED entdecken
Crossref

Evaluation of a new rapid immunochromatographic assay for the detection of GES-producing Gram-negative bacteria

Camille Gonzalez, Hervé Volland, Saoussen Oueslati, Léa Niol, Camille Legrand, Laura Francius, Arnaud Chalin, Anaïs Vogel, Stéphanie Simon, Thierry Naas iD

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Camille Gonzalez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Team 'Resist', UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB),' INSERM, Université Paris-Saclay, CEA, LabE…. Hauptthemen laut MEDLINE: Enterobacteriaceae Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As carbapenemase-producing Enterobacterales are increasingly reported worldwide, their rapid detection is crucial to reduce their spread and prevent infections and outbreaks. Lateral flow immunoassays (LFIAs) have become major tools for the detection of carbapenemases. However, as for most commercially available assays, only the five main carbapenemases are targeted.

Objectives

Here, we have developed and evaluated an LFIA prototype for the rapid and reliable detection of the increasingly identified GES-type β-lactamases.

Methods

The GES LFIA was validated on 103 well-characterized Gram-negative isolates expressing various β-lactamases grown on Mueller–Hinton (MH) agar, chromogenic, and chromogenic/selective media.

Results

The limit of detection of the assay was 106 cfu per test with bacteria grown on MH agar plates. GES LFIA accurately detected GES-type β-lactamases irrespective of the culture media and the bacterial host. The GES LFIA was not able to distinguish between GES-ESBLs and GES-carbapenemases. Because GES enzymes are still rare, their detection as an ESBL or a carbapenemase remains important, especially because extensive use of carbapenems to treat ESBL infections may select for GES variants capable of hydrolysing carbapenems.

Conclusions

The GES LFIA is efficient, rapid and easy to implement in the routine workflow of a clinical microbiology laboratory for the confirmation of GES-type β-lactamases. Combining it with immunochromatographic assays targeting the five main carbapenemases (KPC, NDM, VIM, IMP and OXA-48) would improve the overall sensitivity for the most frequently encountered carbapenemases and ESBLs, especially in non-fermenters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterobacteriaceae InfectionsHumansAgarBacteriological TechniquesSensitivity and Specificitybeta-LactamasesGram-Negative BacteriaCulture MediaCarbapenemsImmunoassay

Substanzen

Agarbeta-LactamasesCulture MediaCarbapenems

Autor:innen und Institutionen

  • Team 'Resist', UMR1184 'Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB),' INSERM, Université Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
  • Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, AP-HP Paris-Saclay, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • Département Médicaments et Technologies pour la Santé, Université Paris-Saclay, CEA, INRAE, 91191 Gif-sur-Yvette, France.
  • Research and Development Department, NG-Biotech, Guipry, France.
  • Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France.

ORCID-Profile: Thierry Naas

Förderung

  • Assistance Publique-Hôpitaux de Paris
  • Université Paris-Saclay
  • Institut National de la Santé et de la Recherche Médicale
  • French National Research Agency

Zitieren

APA

Gonzalez, C., Volland, H., Oueslati, S., Niol, L., Legrand, C., Francius, L., Chalin, A., Vogel, A., Simon, S., & Naas, T. (2023). Evaluation of a new rapid immunochromatographic assay for the detection of GES-producing Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad090

Vancouver

Gonzalez C, Volland H, Oueslati S, Niol L, Legrand C, Francius L, et al. Evaluation of a new rapid immunochromatographic assay for the detection of GES-producing Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad090

BibTeX
@article{Gonzalez2023,
  author = {Gonzalez, Camille and Volland, Hervé and Oueslati, Saoussen and Niol, Léa and Legrand, Camille and Francius, Laura and Chalin, Arnaud and Vogel, Anaïs and Simon, Stéphanie and Naas, Thierry},
  title = {Evaluation of a new rapid immunochromatographic assay for the detection of GES-producing Gram-negative bacteria},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad090}
}
Kostenlos starten →